Home GPCR & G Protein Glucagon Receptor

Glucagon Receptor

GPCR & G Protein

DNA Methyltransferase Histone Demethylase Histone Methyltransferase Epigenetic Reader Domain Histone Acetyltransferase Histone MicroRNA NSD EZH2 RNA Methyltransferase SF3B

Isoform-selective Products

  • All (11)
  • Glucagon Receptor Antagonist (1)
  • Glucagon Receptor Agonists (7)
  • Glucagon Receptor Modulator (1)
  • New Glucagon Receptor Products
Cat.No. Product Name Information Product Use Citations Product Validations
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.
S3734 Albiglutide Fragment Albiglutide fragment is one copy of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36).
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S9697 Semaglutide Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
S9935 Teduglutide Teduglutide (ALX-0600, Gattex, Revestive, TAK 633) is an analogue of human glucagon-like peptide-2 (GLP-2) and binds to the GLP-2 receptors. This compound prolongs the intestinotrophic properties of GLP-2 in animal models.
E4779 DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. This compound attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
E7333 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
E0021 Apraglutide (FE 203799)

Apraglutide (FE 203799) is a potent and highly selective GLP-2 agonist with EC50s of 0.03 nM and 0.07 nM for hGLP-2 Receptor and rGLP-2 Receptor, respectively.
S0555 Adomeglivant Adomeglivant (LY2409021) is a potent and selective antagonist of glucagon receptor that is used as a chronic treatment for type 2 diabetes.
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
S9697 Semaglutide Semaglutide is an oral agonist of glucagon-like peptide-1 receptor (GLP1R), used for treating type 2 diabetes and obesity by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. It is available in subcutaneous and oral formulations.
Cancer Cell, 2025, 43(4):776-796.e14
Nat Commun, 2024, 15(1):7991
S8517 Lixisenatide Lixisenatide (Lyxumia, Adlyxin, ZP10A peptide, AVE0010) is a once-daily short-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with an IC50 of 1.4 nM for the human GLP-1 receptor in receptor binding studies.
E4779 DMB DMB (GLP-1R agonist 2, Compound 2) is an agonist of the GLP-1 receptor (GLP-1R) with a Ki of 13.25 µM. It activates GLP-1R by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues. This compound attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO.
S9307 Shanzhiside methyl ester Shanzhiside methylester is a principle effective iridoid glycoside of L. rotata and serves as a small molecule glucagon-like peptide-1 (GLP-1) receptor agonist.
E7333 Semaglutide Sodium Semaglutide Sodium (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Cancers (Basel), 2025, 17(4)598
E0021 Apraglutide (FE 203799)

Apraglutide (FE 203799) is a potent and highly selective GLP-2 agonist with EC50s of 0.03 nM and 0.07 nM for hGLP-2 Receptor and rGLP-2 Receptor, respectively.
E1173 V-0219 V-0219 is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R), can be used for obesity-associated diabetes research.